North America Companion Animal Diagnostics Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis

The North America Companion Animal Diagnostics Market is poised for significant growth, projected to reach approximately US$ 3,912.2 million by 2031, up from US$ 2,016.9 million in 2024, reflecting a compound annual growth rate (CAGR) of 10.0% from 2025 to 2031. This burgeoning market is primarily driven by increasing pet ownership, advancements in technology, and a rising demand for sophisticated diagnostic tools.

North America, particularly the United States, is at the forefront of this market, which encompasses a variety of diagnostic tools such as clinical chemistry, cytology, and notably, point-of-care testing. The presence of leading animal diagnostics companies and a growing population of companion animals are key factors contributing to this growth. For example, in September 2023, Embark Veterinary formed a partnership with Assistance Dogs International (ADI) to provide DNA testing kits to ADI's breeding cooperative members across North America. This initiative allows for the screening of over 250 genetic health conditions in assistance dogs, promoting healthier breeding practices and extending the service life of these animals.

Major players in the industry, including IDEXX Laboratories, Zoetis, and Thermo Fisher Scientific, are continuously innovating through the development of rapid test kits, AI-integrated diagnostics, and cloud-based veterinary data systems. The adoption of pet insurance and strong support from regulatory bodies like the FDA and USDA have further reinforced the importance of early diagnosis in veterinary care. Additionally, there is a noticeable increase in mobile veterinary services and at-home diagnostic kits, driven by consumer demand for convenience and heightened awareness of pet health.

The market can be segmented by product, companion animal type, technology, application, and end users. In 2024, consumables accounted for the largest market share, followed by instruments. Dogs represented the largest segment among companion animals, while immunodiagnostics led in technology. Clinical pathology was the most significant application area, and veterinary hospitals and clinics were the primary end users.

The integration of artificial intelligence (AI) and data analytics into diagnostic platforms is a transformative trend within the companion animal diagnostics market. For instance, Vetscan Imagyst, an AI-driven technology, offers multiple applications on a single platform, including AI urine sediment analysis, which streamlines diagnostic workflows and enables timely treatment decisions. The development of point-of-care diagnostic capabilities, as exemplified by Vetscan Imagyst, allows veterinarians to perform in-clinic sediment analysis of fresh urine, significantly reducing the time needed to obtain results. This aligns with the growing demand for rapid diagnostics, ultimately improving patient outcomes.

In January 2024, Zoetis expanded its Vetscan Imagyst platform to include AI urine sediment analysis, facilitating accurate in-clinic examinations and enabling quicker treatment decisions. Digital platforms are also enhancing veterinary operations, from appointment scheduling to inventory management, thereby improving service efficiency and allowing veterinarians to focus more on patient care. Mobile applications that assist pet owners with health tracking, vaccination reminders, and educational resources are becoming increasingly popular, reflecting a shift towards more integrated pet care solutions.

Geographically, the North America Companion Animal Diagnostics Market is segmented into the United States, Canada, and Mexico, with the United States holding the largest share in 2024. The growth of the US market is fueled by rising pet ownership, increased veterinary healthcare spending, and technological advancements in diagnostics. The American Pet Products Association reported that approximately 70% of US households own a pet, with pet owners spending around US$ 66 billion on their pets in 2022. This surge in pet ownership, coupled with a growing understanding of the emotional and health benefits of pet companionship, has led to a heightened demand for advanced diagnostic services to manage chronic diseases in companion animals.

Technological innovations and an increase in insured pets are expected to further drive market growth. For instance, Mars, Incorporated's acquisition of SYNLAB Vet in September 2023 enhances diagnostic capabilities and expands access to pet healthcare solutions. Additionally, VolitionRx's launch of the Nu.Q Vet Cancer Test in early 2024 allows for rapid in-clinic cancer screening, providing results in about six minutes, which is particularly beneficial for high-risk breeds and senior dogs.

In summary, the North America Companion Animal Diagnostics Market is on a robust growth trajectory, driven by technological advancements, increasing pet ownership, and a strong focus on early diagnosis and treatment of companion animals. The market's future looks promising, with ongoing innovations and strategic partnerships expected to enhance diagnostic capabilities and improve pet healthcare outcomes.